Amedisys Price Target Maintained With a $101.00/Share by Deutsche Bank
Deutsche Bank Downgrades Amedisys to Hold, Maintains Price Target to $101
Amedisys Analyst Ratings
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Deutsche Bank Downgrades Amedisys to Hold From Buy, Price Target Is $101
TD Cowen Initiates Amedisys(AMED.US) With Hold Rating, Announces Target Price $101
Amedisys: Hold Rating Affirmed Amidst Modest EBITDA Adjustments and Acquisition Offer
Amedisys Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target
TD Cowen Maintains Amedisys(AMED.US) With Hold Rating, Maintains Target Price $101
Amedisys (AMED) Gets a Hold From TD Cowen
Truist Financial Maintains Amedisys(AMED.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Amedisys (AMED) and Draegerwerk AG & Co. KGaA (GB:0K5E)
Jefferies Upgrades UnitedHealth to Buy, Cites Growth Outlook
Amedisys Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Nano-X Imaging (NNOX), Argenx Se (ARGX) and Amedisys (AMED)
Cantor Fitzgerald: Reiterates Amedisys (AMED.US) rating, adjusted from neutral to neutral, with a target price of $101.00.
Amedisys Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)